Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Year: 2018
Type: article
Study design: Clinical Trial
Abstract: Background: Cemiplimab (REGN2810), a human monoclonal antibody to PD-1, has exhibited substantial antitumour activities in patients (pts) with advanced malignancies in a Phase 1 study. Most patients with advanced NSCLC do not respond to PD-1 inhibitor monotherapy. Here we report results of the Phase 1 EC 2, a combination regimen of cemiplimab plus RT in advanced NSCLC (NCT02383212).
Source: Annals of Oncology
Authors: V. Moreno, M. Gil-Martin, M.L. Johnson, R. Aljumaily, P. Lopez Criado, D.W. Northfelt, M. Crittenden, S. Jabbour, L. Rosen, P. Garrido, A. Hervás Morón, P. Rietschel, K.K. Mohan, J. Li, E. Stankevich, M. Feng, I. Lowy, M.G. Fury
Institutions: Hospital Universitario Fundación Jiménez Díaz, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, University of Oklahoma Medical Center, MD Anderson Cancer Center Madrid, Mayo Clinic, Mayo Clinic Hospital, Providence Portland Medical Center, Oregon Clinic, Rutgers Cancer Institute, University of California, Los Angeles, Hospital Universitario Ramón y Cajal, Regeneron (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W4240358470